Sign In
Last checked at 
24 Mar 2014 10:23
Hikma Pharmaceuticals PLC - Vesting of 2011 LTIP
LONDON, 24 March 2014: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received conditional share awards which vested on 24 March 2014 under the 2005 Long Term Incentive Plan ("LTIP") and were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. The persons concerned have retained all the shares exercised.
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.
PDMR | Type of Transaction | Exercised | Date | Price | Shares Disposed | Remaining Holding | ||
Bassam Kanaan
| Vesting of LTIP 2011 | 35,432 (0.02% ISC) | 24 March 2014 | £16.23 | Nil | 503,566 (0.25% ISC) | ||
Michael Raya
| Vesting of LTIP 2011 | 31,776 (0.02% ISC) | 24 March 2014 | £16.23 | Nil | 76,160 (0.04% ISC) | ||
Riad Mishlawi | Vesting of LTIP 2011 | 19,067 (0.01% ISC)
| 24 March 2014 | £16.23 | Nil | 79,327 (0.04% ISC) | ||
Khalid Nabilsi | Vesting of LTIP 2011 | 26,011 (0.01% ISC)
| 24 March 2014 | £16.23 | Nil | 196,858 (0.10% ISC) | ||
| ||||||||
- ENDS -
Enquiries
Peter Speirs +44 20 7399 2760
Company Secretary, Hikma Pharmaceuticals PLC
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.
Follow the stocks
